Q1 2025 Aquestive Therapeutics Inc Earnings Call Transcript
Key Points
- Aquestive Therapeutics Inc (AQST) is in the commercial prelaunch phase for Anaphylm, a potentially transformative oral medication for severe allergic reactions, with FDA approval anticipated in early 2026.
- The company has assembled a strong marketing team with experience in building successful brands like EpiPen, positioning them well for a successful launch.
- Aquestive has established significant relationships with national allergy advocacy groups and is actively involved in shaping legislative actions to ensure patient access to epinephrine products.
- The company has a robust prelaunch awareness platform, having attended numerous conferences and published multiple posters and manuscripts to increase awareness among healthcare professionals.
- Aquestive's in-house manufacturing capabilities ensure readiness for product launch, with plans in place to have Anaphylm available on day one of approval.
- Total revenues decreased by 28% in the first quarter of 2025 compared to the same period in 2024, primarily due to declines in manufacture and supply revenue and license and royalty revenue.
- The company reported a net loss of $22.9 million for the first quarter of 2025, an increase from the $12.8 million loss in the first quarter of 2024.
- Selling, general, and administrative expenses increased significantly, driven by regulatory fees, legal fees, and higher commercial spending.
- Aquestive has paused sales and marketing activities for Libervant, impacting revenue guidance for 2025.
- The company acknowledges the need to strengthen its balance sheet ahead of the Anaphylm launch, indicating potential financial challenges in supporting the launch without additional capital.
Good day, and thank you for standing by. Welcome to the Aquestive Therapeutics first quarter 2025 earnings conference call. (Operator Instructions) Please be advised today's conference is being recorded.
I would now like to turn the conference over to your host today, Brian Korb. Please go ahead.
Thank you, operator. Good morning, and welcome to today's call. On today's call, I'm joined by Dan Barber, Chief Executive Officer; and Ernie Toth, Chief Financial Officer. We're going to provide an overview of recent business developments and performance for the first quarter of 2025 followed by a Q&A session. During the Q&A session, the team will be joined by Dr. Carl Kraus, Chief Medical Officer; and Sherry Korczynski, Senior Vice President, Sales and Marketing.
As a reminder, the company's remarks today correspond with the earnings release that was issued after market close yesterday. In addition, a recording of today's call will be made available on Aquestive's website within the Investors
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
